$-0.26 EPS Expected for Marrone Bio Innovations, Inc. (MBII)

March 15, 2018 - By Max Morgan

 $ 0.26 EPS Expected for Marrone Bio Innovations, Inc. (MBII)
Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.08, from 0.86 in 2017Q2. It fall, as 3 investors sold Marrone Bio Innovations, Inc. shares while 6 reduced holdings. 6 funds opened positions while 1 raised stakes. 11.77 million shares or 0.87% less from 11.88 million shares in 2017Q2 were reported.
Azimuth Mngmt Ltd Limited Liability Company owns 35,000 shares for 0% of their portfolio. Raymond James Fincl Advsr accumulated 16,061 shares. Royal National Bank Of Canada invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Waddell & Reed Fin Inc reported 0.01% stake. State Street owns 10,800 shares. Spark Inv Mngmt Ltd has 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Morgan Stanley holds 480 shares or 0% of its portfolio. Ardsley Advisory Prns owns 3.68 million shares. Northern Trust Corporation, a Illinois-based fund reported 24,737 shares. Primecap Ca has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Vanguard Gp Incorporated accumulated 0% or 388,655 shares. Virtu Lc invested in 0% or 20,446 shares. 11,088 were accumulated by Two Sigma Securities Limited Co. Art Advsr Ltd Liability holds 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 23,171 shares. Hanson Mcclain invested 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII).

Since February 5, 2018, it had 1 insider purchase, and 0 insider sales for $5.00 million activity.

Analysts expect Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report $-0.26 EPS on April, 4.They anticipate $0.06 EPS change or 18.75 % from last quarter’s $-0.32 EPS. After having $-0.27 EPS previously, Marrone Bio Innovations, Inc.’s analysts see -3.70 % EPS growth. The stock decreased 2.94% or $0.05 during the last trading session, reaching $1.65. About 287,641 shares traded or 130.50% up from the average. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 94.03% since March 15, 2017 and is uptrending. It has outperformed by 77.33% the S&P500.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Ratings Coverage

Among 4 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marrone Bio Innovations had 7 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, July 21 by Piper Jaffray. As per Tuesday, August 11, the company rating was downgraded by Zacks. The company was maintained on Thursday, February 8 by Jefferies. Piper Jaffray maintained Marrone Bio Innovations, Inc. (NASDAQ:MBII) on Friday, September 15 with “Hold” rating. H.C. Wainwright maintained it with “Buy” rating and $3.5000 target in Tuesday, August 15 report. The firm has “Hold” rating by Piper Jaffray given on Monday, August 14. The stock has “Buy” rating by Rodman & Renshaw on Wednesday, March 16.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $168.08 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

More notable recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Bizjournals.com which released: “Marrone Bio clears away most debt, gets a new chairman” on February 06, 2018, also Globenewswire.com with their article: “Marrone Bio Innovations Announces Distribution Partnership in the Philippines” published on January 25, 2018, Globenewswire.com published: “Marrone Bio Innovations, Inc. Announces Stockholder Approval of Private …” on February 01, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) were released by: Globenewswire.com and their article: “Marrone Bio Innovations and DISAGRO Sign Exclusive Distribution Agreement for …” published on December 20, 2017 as well as Seekingalpha.com‘s news article titled: “Short Squeeze Coming In Marrone Bio Innovations?” with publication date: August 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.